What are the recommended sclerotherapy dosing guidelines for macrocystic lymphatic malformations using agents such as OK‑432 (picibanil), doxycycline, bleomycin, ethanol, and sodium tetradecyl sulfate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Sclerotherapy Dosing for Macrocystic Lymphatic Malformations

Recommended First-Line Agent and Dosing

Doxycycline is the preferred sclerosing agent for macrocystic lymphatic malformations, administered at 10 mg/kg (maximum 1000 mg) diluted in 10-20 mL of normal saline or contrast, injected percutaneously under image guidance. 1

Agent-Specific Dosing Guidelines

Doxycycline (Preferred Agent)

  • Dose: 10 mg/kg per session, maximum 1000 mg 1
  • Preparation: Dilute in 10-20 mL normal saline or contrast medium 2
  • Administration: Percutaneous injection under ultrasound or fluoroscopic guidance 1
  • Treatment sessions: Average 2.8 treatments (range 1-7) to achieve excellent/moderate response 1
  • Success rate: 87% achieve >50% reduction in lesion size 1
  • Interval between treatments: Typically 4-6 weeks, based on clinical response 2

OK-432 (Picibanil)

  • Dose: 0.1-0.2 mg per session 2, 3
  • Preparation: Reconstitute with 5-10 mL normal saline 2
  • Administration: Direct intralesional injection under image guidance 2
  • Treatment sessions: Average 1.9 treatments required (significantly more than doxycycline) 3
  • Success rate: 83% clinical success, similar to doxycycline 3
  • Key limitation: Requires more treatment sessions and causes marked postoperative swelling 3

Bleomycin (For Microcystic Lesions)

  • Dose: Up to 1 U/kg per session, maximum 15 U total dose 4
  • Administration: Percutaneous image-guided injection 4
  • Treatment sessions: Average 1.7 procedures (range 1-4) 4
  • Success rate: 96% achieve >25% reduction (38% complete response, 58% partial response) 4
  • Safety monitoring: Mandatory pulmonary function tests at baseline, 6 months, and 1 year; annual chest X-rays 4
  • Indication: Specifically effective for microcystic or combined lesions where other agents fail 4

Sodium Tetradecyl Sulfate (STS)

  • Dose: 3% concentration, volume adjusted to lesion size 1
  • Success rate: Only 55% achieve >50% reduction 1
  • Key limitation: Significantly inferior to doxycycline (P = 0.03) and requires more subsequent surgical resection (33% vs 13%) 1
  • Recommendation: Should not be used as first-line monotherapy 1

Ethanolamine Oleate

  • Dose: Volume-adjusted based on cyst size 2
  • Success rate: Similar effectiveness to doxycycline and OK-432 in head/neck lesions 2
  • Radiologic response: 84.5% average volume reduction 2

Ethanol

  • Use: Mentioned in literature but no specific pediatric dosing guidelines provided in the evidence 2
  • Caution: Higher risk of tissue necrosis and nerve injury; generally reserved for refractory cases 2

Treatment Algorithm by Lesion Type

Macrocystic Lesions (>2 cm cysts)

  1. First-line: Doxycycline 10 mg/kg (max 1000 mg) 1
  2. Alternative: OK-432 0.1-0.2 mg if doxycycline unavailable 2, 3
  3. Second-line: Ethanolamine oleate if first-line fails 2
  4. Avoid: STS monotherapy due to inferior outcomes 1

Microcystic Lesions (<2 cm cysts)

  1. First-line: Bleomycin up to 1 U/kg (max 15 U) 4
  2. Monitoring: Mandatory PFTs and chest imaging due to pulmonary fibrosis risk 4

Mixed Lesions (Macrocystic + Microcystic)

  1. First-line: Doxycycline 10 mg/kg for macrocystic component 1
  2. Consider: Bleomycin for persistent microcystic areas 4

Practical Administration Details

Pre-Procedure Requirements

  • Image guidance (ultrasound or fluoroscopy) mandatory for all agents 4, 2, 1
  • Aspiration of cyst fluid before sclerosant injection 2
  • General anesthesia typically required in pediatric patients 3

Operating Room Time

  • Doxycycline: Average 98 minutes per session 3
  • OK-432: Average 53 minutes per session (but requires more total sessions) 3

Post-Procedure Monitoring

  • Doxycycline: Minimal swelling, outpatient observation sufficient 3
  • OK-432: Marked postoperative swelling requiring extended monitoring 3
  • Bleomycin: PFTs at 6 months and 1 year; annual chest X-rays 4

Common Pitfalls to Avoid

  1. Do not use STS as monotherapy – 45% failure rate and 33% require subsequent surgery 1

  2. Do not exceed bleomycin maximum dose – Cumulative lifetime dose >15 U increases pulmonary fibrosis risk 4

  3. Do not skip pulmonary monitoring with bleomycin – Mandatory PFTs and chest imaging are non-negotiable 4

  4. Do not expect single-treatment cure – Average 2-3 sessions required for most agents 2, 3, 1

  5. Do not use doxycycline in children <8 years without informed consent – Risk of permanent tooth discoloration, though this must be weighed against surgical morbidity 3

  6. Do not inject sclerosant without prior cyst aspiration – Reduces effective concentration and treatment response 2

Comparative Effectiveness Summary

Doxycycline demonstrates superior outcomes compared to other agents: 87% excellent/moderate response with fewer treatments (average 2.8) and only 13% requiring subsequent resection, compared to 55% response and 33% resection rate with STS 1. OK-432 achieves similar success rates (83%) but requires significantly more treatment sessions (1.9 vs 1.0, P = 0.01) and causes more postoperative swelling 3. Bleomycin is uniquely effective for microcystic lesions (96% response rate) but requires intensive pulmonary safety monitoring 4.

References

1
Research

Doxycycline Sclerotherapy Is Superior in the Treatment of Pediatric Lymphatic Malformations.

Journal of vascular and interventional radiology : JVIR, 2016

3
Research

OK432 versus doxycycline for treatment of macrocystic lymphatic malformations.

The Annals of otology, rhinology, and laryngology, 2014

Related Questions

What is the recommended management for a mature mediastinal teratoma?
I increased my antihypertensive medication dose yesterday; how long should I wait for its full effect before adding another agent if my blood pressure remains elevated?
What is the likely cause of hand symptoms that worsen while washing clothes and feel cold, with possible numbness or tingling in the thumb, index, and middle fingers?
What are the recommended pre‑medication, monitoring, and management steps for infusion‑related reactions to zolbetuximab (anti‑CLDN18.2 monoclonal antibody) in patients with advanced gastric or gastro‑esophageal adenocarcinoma?
How should I define urine output criteria (normal, oliguria, anuria, and KDIGO AKI stages) for adults and children to assess renal perfusion?
What is the normal total and free testosterone range for a healthy 55‑year‑old male?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.